HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Gerhard Moldenhauer Selected Research

Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)

3/2015Antibody therapy to human L1CAM in a transgenic mouse model blocks local tumor growth but induces EMT.
6/2014A standardized staining protocol for L1CAM on formalin-fixed, paraffin-embedded tissues using automated platforms.
1/2013L1 cell adhesion molecule as a potential therapeutic target in murine models of endometriosis using a monoclonal antibody approach.
6/2012Combined treatment of L1CAM antibodies and cytostatic drugs improve the therapeutic response of pancreatic and ovarian carcinoma.
1/2012Myofibroblast-induced tumorigenicity of pancreatic ductal epithelial cells is L1CAM dependent.
10/2010Elevated L1CAM expression in precursor lesions and primary and metastastic tissues of pancreatic ductal adenocarcinoma.
3/2010Therapeutic antibodies to human L1CAM: functional characterization and application in a mouse model for ovarian carcinoma.
3/2010Expression of L1CAM, COX-2, EGFR, c-KIT and Her2/neu in anaplastic pancreatic cancer: putative therapeutic targets?
8/2006Expression profile analysis in multiple human tumors identifies L1 (CD171) as a molecular marker for differential diagnosis and targeted therapy.
1/2006Efficient inhibition of intra-peritoneal tumor growth and dissemination of human ovarian carcinoma cells in nude mice by anti-L1-cell adhesion molecule monoclonal antibody treatment.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Gerhard Moldenhauer Research Topics

Disease

36Neoplasms (Cancer)
11/2021 - 09/2002
10Carcinoma (Carcinomatosis)
01/2021 - 09/2002
7Neoplasm Metastasis (Metastasis)
03/2015 - 06/2007
7Pancreatic Neoplasms (Pancreatic Cancer)
04/2012 - 10/2005
5Lymphoma (Lymphomas)
03/2022 - 11/2004
4B-Cell Lymphoma (Lymphoma, B Cell)
03/2022 - 07/2007
4Breast Neoplasms (Breast Cancer)
01/2021 - 11/2009
4Adenocarcinoma
03/2015 - 10/2010
3Hematologic Neoplasms (Hematological Malignancy)
01/2021 - 08/2013
3Melanoma (Melanoma, Malignant)
03/2015 - 08/2006
3Non-Hodgkin Lymphoma (Lymphosarcoma)
12/2014 - 11/2004
3Ascites
05/2012 - 09/2002
2Hepatocellular Carcinoma (Hepatoma)
11/2021 - 08/2013
2Infections
11/2021 - 01/2019
2Endometrial Neoplasms (Endometrial Cancer)
06/2014 - 08/2006
2Colorectal Neoplasms (Colorectal Cancer)
04/2012 - 06/2007
2Carcinogenesis
01/2012 - 10/2010
2Renal Cell Carcinoma (Grawitz Tumor)
07/2010 - 01/2006
2Colonic Neoplasms (Colon Cancer)
06/2007 - 08/2006
1Chronic Hepatitis B
11/2021
1Hepatitis
11/2021
1Malaria
01/2019
1Fibrosis (Cirrhosis)
01/2016
1Neurilemmoma (Schwannoma)
04/2014
1Leiomyosarcoma
04/2014
1Liposarcoma
04/2014
1Hemangiosarcoma (Angiosarcoma)
04/2014
1Chondrosarcoma
04/2014
1Sarcoma (Soft Tissue Sarcoma)
04/2014
1Synovial Sarcoma (Synovioma)
04/2014
1Myxoid Liposarcoma
04/2014
1Neurofibrosarcoma (MPNST)
04/2014
1Solitary Fibrous Tumors
04/2014
1Head and Neck Neoplasms (Head and Neck Cancer)
01/2014
1Endometriosis
01/2013
1Pathologic Complete Response
04/2012
1Prostatic Neoplasms (Prostate Cancer)
02/2012

Drug/Important Bio-Agent (IBA)

11AntibodiesIBA
11/2021 - 01/2005
11Epithelial Cell Adhesion MoleculeIBA
01/2021 - 12/2002
10Proteins (Proteins, Gene)FDA Link
03/2022 - 01/2005
10Neural Cell Adhesion Molecule L1 (L1 Cell Adhesion Molecule)IBA
03/2015 - 01/2006
7Monoclonal AntibodiesIBA
03/2022 - 01/2006
6AntigensIBA
01/2021 - 12/2002
5Immunoglobulin G (IgG)IBA
01/2014 - 12/2002
3EpitopesIBA
03/2022 - 07/2010
3Bispecific AntibodiesIBA
01/2021 - 12/2002
3Pharmaceutical PreparationsIBA
08/2015 - 01/2011
3LigandsIBA
07/2014 - 02/2012
3Messenger RNA (mRNA)IBA
08/2013 - 11/2008
2Suppressor of Cytokine Signaling 1 ProteinIBA
03/2022 - 07/2021
2CytokinesIBA
01/2021 - 11/2009
2Glycoproteins (Glycoprotein)IBA
01/2016 - 01/2013
2Biomarkers (Surrogate Marker)IBA
06/2014 - 08/2006
2Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2012 - 09/2002
2AutoantibodiesIBA
04/2012 - 01/2005
2sulforaphaneIBA
01/2011 - 09/2010
2Therapeutic UsesIBA
03/2010 - 09/2002
2Protein Isoforms (Isoforms)IBA
06/2007 - 10/2005
2TetraspaninsIBA
06/2007 - 10/2005
2Muromonab-CD3 (Muromonab CD3)FDA Link
12/2002 - 09/2002
1Antiviral Agents (Antivirals)IBA
11/2021
1Hepatitis B Surface Antigens (HBsAg)FDA Link
11/2021
1Peptides (Polypeptides)IBA
01/2019
1VaccinesIBA
01/2019
1ProteomeIBA
01/2019
1B-Lymphocyte Epitopes (B-Cell Epitope)IBA
01/2019
1Malaria VaccinesIBA
01/2019
1Epidermal Growth Factor (EGF)IBA
03/2015
1Photosensitizing Agents (Photosensitizers)IBA
01/2015
1tetra(3-hydroxyphenyl)porphineIBA
01/2015
1Chemokine ReceptorsIBA
12/2014
1CD3 ComplexIBA
12/2014
1Small Interfering RNA (siRNA)IBA
07/2014
1Natural Killer Cell ReceptorsIBA
07/2014
1Metalloproteases (Metalloproteinases)IBA
07/2014
1DisintegrinsIBA
07/2014
1Peptide Hydrolases (Proteases)FDA Link
07/2014
1ADAM17 ProteinIBA
07/2014
1Natural Cytotoxicity Triggering Receptor 3IBA
07/2014
1Neurofibromin 1 (Neurofibromin)IBA
04/2014
1Histone Deacetylase InhibitorsIBA
08/2013
1Neural Cell Adhesion Molecules (Neural Cell Adhesion Molecule)IBA
01/2013
1Membrane Proteins (Integral Membrane Proteins)IBA
11/2012
1Glycosylphosphatidylinositols (Glycosyl-Phosphatidylinositol)IBA
11/2012
1Cytostatic AgentsIBA
06/2012
1Caspase 8 (Caspase-8)IBA
06/2012
1Paclitaxel (Taxol)FDA LinkGeneric
06/2012
1GemcitabineFDA Link
06/2012
1catumaxomabIBA
05/2012
1ThymidineIBA
04/2012
1AmanitinsIBA
04/2012
1taxaneIBA
04/2012
1AnthracyclinesIBA
04/2012
1Death Domain ReceptorsIBA
02/2012

Therapy/Procedure

16Therapeutics
11/2021 - 09/2002
6Immunotherapy
12/2014 - 12/2002
3Drug Therapy (Chemotherapy)
01/2015 - 09/2002
1Lasers (Laser)
01/2019
1Heterologous Transplantation (Xenotransplantation)
01/2013
1Neoadjuvant Therapy
04/2012